Selected article for: "acute kidney injury and long term effect"

Author: Chen, Cheng-Yi; Wu, Vin-Cent; Lin, Cheng-Jui; Lin, Chih-Sheng; Pan, Chi-Feng; Chen, Han-Hsiang; Lin, Yu-Feng; Huang, Tao-Min; Chen, Likwang; Wu, Chih-Jen
Title: Improvement in Mortality and End-Stage Renal Disease in Patients With Type 2 Diabetes After Acute Kidney Injury Who Are Prescribed Dipeptidyl Peptidase-4 Inhibitors
  • Cord-id: 0vlgfbar
  • Document date: 2018_10_19
  • ID: 0vlgfbar
    Snippet: OBJECTIVE: To focus on the potential beneficial effects of the pleiotropic effects of dipeptidyl peptidase-4 inhibitors (DPP4is) on attenuating progression of diabetic kidney disease in reducing the long-term effect of the acute kidney injury (AKI) to chronic kidney disease (CKD) transition. PATIENTS AND METHODS: Data from the National Health Insurance Research Database from January 1, 1999, to July 31, 2011, were analyzed, and patients with diabetes weaning from dialysis-requiring AKI were iden
    Document: OBJECTIVE: To focus on the potential beneficial effects of the pleiotropic effects of dipeptidyl peptidase-4 inhibitors (DPP4is) on attenuating progression of diabetic kidney disease in reducing the long-term effect of the acute kidney injury (AKI) to chronic kidney disease (CKD) transition. PATIENTS AND METHODS: Data from the National Health Insurance Research Database from January 1, 1999, to July 31, 2011, were analyzed, and patients with diabetes weaning from dialysis-requiring AKI were identified. Cox proportional hazards models and inverse-weighted estimates of the probability of treatment were used to adjust for treatment selection bias. The outcomes were incident end-stage renal disease (ESRD) and mortality, major adverse cardiovascular events, and hospitalized heart failure. RESULTS: Of a total of 6165 patients with diabetes weaning from dialysis-requiring AKI identified, 5635 (91.4%) patients were DPP4i nonusers and 530 (8.6%) patients were DPP4i users. Compared with DPP4i nonusers, DPP4i users had a lower risk of ESRD (hazard ratio, 0.81; 95% CI, 0.70-0.94; P=.04) and all-cause mortality (hazard ratio, 0.28; 95% CI, 0.23-0.34; P<.001) after adjustments for CKD, advanced CKD, and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use. In contrast, the risk of major adverse cardiovascular events and hospitalized heart failure did not differ significantly between groups. CONCLUSION: Dipeptidyl peptidase-4 inhibitor users had a lower risk of ESRD and mortality than did nonusers among patients with diabetes after weaning from dialysis-requiring AKI. Therefore, a prospective study of AKI to CKD transitions after episodes of AKI is needed to optimally target DPP4i interventions.

    Search related documents:
    Co phrase search for related documents
    • acute aki kidney injury and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute aki kidney injury and long term dialysis: 1, 2
    • acute aki kidney injury and long term mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute aki kidney injury and long term persist: 1
    • acute aki kidney injury and long term survival: 1, 2
    • acute aki kidney injury risk and logistic regression: 1, 2, 3, 4, 5, 6, 7
    • acute aki kidney injury risk and long term persist: 1
    • acute kidney injury and adaptive immune system: 1
    • acute kidney injury and local inflammatory response: 1
    • acute kidney injury and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute kidney injury and long term dialysis: 1, 2
    • acute kidney injury and long term mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acute kidney injury and long term persist: 1
    • acute kidney injury and long term survival: 1, 2
    • acute renal failure and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute renal failure and long term mortality: 1, 2, 3
    • acute renal failure and long term survival: 1, 2, 3
    • adaptive immune system and long term mortality: 1
    • adjusted hrs and logistic regression: 1, 2